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Graft-Speciﬁc HLA-Antibodies Do Not Inﬂuence Unit
Dominance and Do Not Prevent High Rates of Sustained
Donor Engraftment in Recipients of Double-Unit Cord
Blood (CB) Transplantation
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Background: While HLA-antibodies (Ab) have an estab-
lished role in failed engraftment after single-unit CB trans-
plantation (CBT), their role in double-unit CBT (DCBT)
engraftment is more controversial.
Methods:We evaluated the inﬂuence of pre-transplant HLA-
Ab on sustained donor neutrophil engraftment & unit
dominance in 82 recipients (median age 48, range 2-69) of 4-
6/6 HLA-A,B antigen, DRB1 allele matched double-unit CB
grafts, & transplanted for hematologic malignancies from 7/
2008-7/2012. HLA-Ab were measured by the American Red
Cross Blood Service using Single Antigen Luminex beads &
analyzed by HLA Fusion software. The cut-off for positive
results was a normalized mean ﬂuorescence intensity value
> 1000.
Results: 28/82 (34%) patients were positive for HLA-Ab [16
(19.5%) had Ab without graft speciﬁcity, & 12 (14.5%) had Ab
with graft speciﬁcity]. These patients were more likely to be
female with acute leukemia & CMV seropositive. All patients
with graft-speciﬁc Ab receivedmyeloablative conditioning; 5
had Ab against class I HLA, 6 against class II, & one patient
had Ab to both Class I/II. Moreover, of these 12 patients, 6 had
Ab against one unit & 6 had Ab against both units. Neutrophil
engraftment according to Ab is summarized in the Table.Table
Sustained Donor Neutrophil Engraftment According to HLA-Ab
1A) Myeloablative Conditioning (n ¼ 67)
Median (Range)
Time to Neutrophil
Recovery (0.5)
N (%) Sustained
Engraftment
No Ab (n ¼ 41) 23 days (range 12-38) 39/40
(1 non-evaluable)
Ab: not graft-speciﬁc
(n ¼ 14)
23 days (range 12-37) 14/14
Ab: graft-speciﬁc
(n ¼ 12)
31 days (range 13-40) 11/12
Against engrafting unit
(n ¼ 3)
28 days (range 24-31) 3/3
Against non-engrafting
unit (n ¼ 3)
31 days (range 25-32) 3/3
Against both units
(n ¼ 6)
33 days (range 13-40) 5/6
1B) Non-Myeloablative Conditioning (n ¼ 15)
Median (Range)
Time to Neutrophil
Recovery ( 0.5)
N (%) Sustained
Engraftment
No Ab (n ¼ 13) 10 days (range 8-20) 13/13
Ab: not graft speciﬁc
(n ¼ 2)
19 days in 1 patient
(other had autologous
recovery)
1/2
Ab: graft speciﬁc (n ¼ 0) - -64/66 (97%) evaluable myeloablative DCBT recipients (Table
1A) engrafted at a median of 24 days (range 12-40); one
patient without Ab & one with Ab against both units had
primary graft failure, both in the setting of early onset multi-
organ failure. Both patients were 100% donor in the marrow
with one unit but did not recover counts. Of the 6 patients
with Ab to one unit, 3 engrafted with that unit & 3 with the
opposite unit. Of the 6 patients with Ab against both units,
one had clinical graft failure as described above, & the 5
others had sustained donor engraftment (4 with one unit &
one with both). In engrafting myeloablative recipients, the
median time to neutrophil recovery was 8 days slower in
patients with graft-speciﬁc Ab, but the engrafting unit in
these patients also had the lowest infused dose: median
CD34+ cell dose/kg if no Ab 0.83 x 105/kg, non-speciﬁc Ab
1.09 x 105/kg, & Ab speciﬁc to graft 0.65 x 105/kg. In non-
myeloablative recipients, 15/16 (94%) engrafted (Table 1B).
The single patient with rejection/ autologous recovery had
Ab that were not graft speciﬁc.
Conclusions: 11/12 double-unit CBT recipients with graft-
speciﬁc Ab engrafted successfully. While myeloablative
recipients with graft-speciﬁc Ab engrafted more slowly, this
may be explained by their lower infused CD34+ cell dose.
While multivariate analysis of larger series will be required
to further evaluate the effect of graft-speciﬁc Ab on
engraftment speed, currently the presence of graft-speciﬁc
Ab should not preclude DCBT, & whether their presence
should inﬂuence graft selection is unclear. Moreover, there is
no suggestion that HLA-Ab inﬂuence unit dominance after
DCBT.
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The Effect of Donor Characteristics on Graft vs. Host
Disease (GVHD) and Survival after Unrelated Donor Trans-
plantation for Hematologic Malignancy.
Craig Kollman, John Klein, Stephen Spellman, Anna Has-
sebroek, Dennis Confer, Marcelo Fernandez-Vina, Robert
Hartzman, Carolyn K Hurley, Martin Maiers, Carlheinz
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We analyzed 6,349 adult unrelated donor trans-
plantations performed in 1988e2006 to reexamine the effect
of donor age and other donor characteristics including
donor-recipient HLA matching on transplant outcomes.
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MDS) and approximately 40% were in ﬁrst complete remis-
sion or ﬁrst chronic phase. 93% of transplantations used
donors younger than 50 (median 35.8, range 18-61). The
majority of patients received myeloablative preparative
regimens (88%) and bone marrow grafts (62%). All patients
received calcineurin inhibitor containing GVHD prophylaxis
and 20% received in vivo T cell depletion. We identiﬁed three
donor characteristics associated with overall survival; donor
age, high resolution donor-recipient HLA-match and ABO
blood group match. Risk adjusted 5-year survival rates were
37%, 33% and 29% with donors aged 18-32, 33-50, and >50
years, respectively (p<0.0001). Corresponding hazard ratios
were 1.13 (p¼0.0004) for donors aged 33e50 years and 1.29
(p<0.001) for donors >50 years compared with donors aged
18 e 32 years. Mortality risks were higher with one (HR 1.24,
P < .0001) and two (HR 1.62, P < .0001) HLA-mismatches
compared with HLA-matched transplants and minor (HR
1.10, P ¼ .002) or major (HR 1.13, P ¼ .001) ABO blood group
mismatch compared with ABO-matched transplants. A sub-
analysis investigated the possibility that the associationwith
donor age may be due to underlying genetic disparity
between donor and recipient. That is, recipients with rare
HLA genotypes tend to have fewer matched donors to choose
from and thus more likely to receive a graft from an older
donor. Recipient genotypes were assigned to quartiles using
frequency data from 4 million NMDP donors as a reference.
The lowest frequency quartile was associated with donors
older than 50 (p<0.0001) and higher rates of HLA mis-
matching (p<0.001) but no association was found between
genotype frequency and overall mortality. Acute GVHD risks
were associated with donor age and HLA match and, donor
parity, the only donor characteristic associated with chronic
GVHD (table). In summary, the data recommend the
consideration of donor age and ABO blood group match to
maximize survival when selecting among comparably HLA-
matched adult unrelated stem cell donors for treatment of
a hematologic malignancy.68
Higher Infused CD34+ Dose Positively Inﬂuence Platelet
Recovery After Cord Blood Transplantation
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Background: Umbilical cord blood transplantation (UCBT) is
associated with delay in platelet recovery. However, the
underlying factors inﬂuencing this delayed recovery remain
poorly understood. With the aim of identifying factors that
inﬂuence platelet engraftment, we retrospectively analyzed
data from 68 consecutive myeloablative UCBT recipients
transplanted between April 2006 and March 2012.
Methods: Forty-two (62%) patients received high-dose TBI
(1320 cGy), cyclophosphamide and ﬂudarabine (FLU); while
26 (38%) received Treosulfan, FLU, and a single fraction of
200cGy TBI. Graft-versus-host-disease (GVHD) prophylaxis
consisted of cyclosporine and mycophenolate mofetil.
Platelet recovery was deﬁned as the ﬁrst day of a platelet
count 20 and 50 x 109/L without transfusion for 7 days.
Cumulative incidence (CI) curves were used to estimate the
probabilities of platelet engraftment in the ﬁrst 100 days
post- transplant. A proportional hazards regression model
was used to evaluate the association between CD34+ celldose and platelet engraftment. Factors considered as
potential predictors or confounders included age at trans-
plant, sex, race, body mass index (BMI), disease risk, CMV
seropositivity, presence of minimal residual disease at
transplant (MRD), number of UCB units infused, acute GVHD,
total nucleated cells (TNC) and CD34+ cells.
Results:Median age and BMIwere 36 years (range,1-63) and
26 kg/m2 (range, 16-41), respectively. The majority of
patients (88%) received 2 cord blood units (n¼60). Twenty-
seven (40%) hadMRD and 46 (68%) were CMV seropositive at
time of transplant. Median total infused cell doses were: 3.9
x 107 TNC/kg (range: 2.2-11.2) and 0.25 x 106 CD34+ cells/kg
(range: 0.09 e 1.46). The 100-day CI of platelet engraftment
was 65% (95% CI: 53-76%) for platelets 20 109/L and 59%
(95% CI: 47-71%) for platelets 50 109/L. In univariate anal-
ysis higher CD34+ infused dose was signiﬁcantly associated
with platelet engraftment [HR¼1.4 (95% CI: 1.0-1.9, P ¼ .03)].
Furthermore, platelet engraftment was suggestively slower
among patients with higher BMI [HR¼0.9 (95% CI: 0.9-1.0, P
¼ .06)] while presence of aGVHD grade III-IV was associated
with higher rate of engraftment [HR¼2.1 (95% CI: 0.8-5.9, P¼
.07)]. No signiﬁcant associations were found between all the
others factors analyzed and platelet recovery.In multivari-
able analysis the association between larger CD34+ dose and
higher rate of engraftment remained statistically signiﬁcant
[HR¼1.9 (95% CI: 1.3-2.8, P < .001]. In addition, CMV sero-
positivity [HR¼0.4 (95% CI: .0.2-0.9, P ¼ .02)] became
signiﬁcantly associated with a slower rate of engraftment.
Conclusions: These results indicate that the infused CD34+
dose is a strong independent predictor of platelet engraft-
ment. Furthermore we should expect an earlier sustained
platelet recovery among CMV seronegative patients.IMMUNE RECONSTITUTION ORAL
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Ultra-Low Dose IL-2 Expands Natural Regulatory T Cells
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and Is Associated with Clinical Improvement in Chronic
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Low dose interleukin-2 (IL-2) can increase regulatory T
cells (Treg) and has therapeutic beneﬁt in steroid refractory
cGVHD. To further deﬁne immunological changes underlying
the response to IL-2 and to determine tolerability, we per-
formed phenotypic characterization and functional analysis
of Treg and natural killer (NK) cells in individuals given IL-2.
Six healthy volunteers received subcutaneous ultra low dose
IL-2 (0.2MIU/m2/day) for 5 days without signiﬁcant side
effects. Two patients with steroid and calcineurin-refractory
cGVHD received the same dose of IL-2 daily for 4 or 8 weeks,
after HLA identical myeloablative stem cell transplant (SCT)
for AML. Patient 1 (50 year old male, 3 yr post SCT) had skin
and fascial GVHD affecting the lower limbs. Patient 2 (44 year
old female, 2 yr post SCT) had upper gastrointestinal cGVHD.
Both patients had a prompt and durable partial response by
